JP2015523386A - 寛容を誘導するために正常ｂ細胞を枯渇させるためのｃａｒｔ１９の使用 - Google Patents

寛容を誘導するために正常ｂ細胞を枯渇させるためのｃａｒｔ１９の使用 Download PDF

Info

Publication number
JP2015523386A
JP2015523386A JP2015521846A JP2015521846A JP2015523386A JP 2015523386 A JP2015523386 A JP 2015523386A JP 2015521846 A JP2015521846 A JP 2015521846A JP 2015521846 A JP2015521846 A JP 2015521846A JP 2015523386 A JP2015523386 A JP 2015523386A
Authority
JP
Japan
Prior art keywords
cells
cell
car
cart19
genetically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015521846A
Other languages
English (en)
Japanese (ja)
Inventor
ブルース エル． レービン
ブルース エル． レービン
マイケル ディー． カロス
マイケル ディー． カロス
カール エイチ． ジューン
カール エイチ． ジューン
Original Assignee
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア, ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア filed Critical ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Publication of JP2015523386A publication Critical patent/JP2015523386A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015521846A 2012-07-13 2013-07-12 寛容を誘導するために正常ｂ細胞を枯渇させるためのｃａｒｔ１９の使用 Withdrawn JP2015523386A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261671508P 2012-07-13 2012-07-13
US61/671,508 2012-07-13
PCT/US2013/050293 WO2014012001A2 (en) 2012-07-13 2013-07-12 Use of cart19 to deplete normal b cells to induce tolerance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018082149A Division JP2018135363A (ja) 2012-07-13 2018-04-23 寛容を誘導するために正常ｂ細胞を枯渇させるためのｃａｒｔ１９の使用

Publications (1)

Publication Number Publication Date
JP2015523386A true JP2015523386A (ja) 2015-08-13

Family

ID=49916701

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015521846A Withdrawn JP2015523386A (ja) 2012-07-13 2013-07-12 寛容を誘導するために正常ｂ細胞を枯渇させるためのｃａｒｔ１９の使用
JP2018082149A Withdrawn JP2018135363A (ja) 2012-07-13 2018-04-23 寛容を誘導するために正常ｂ細胞を枯渇させるためのｃａｒｔ１９の使用
JP2020113687A Withdrawn JP2020158541A (ja) 2012-07-13 2020-07-01 寛容を誘導するために正常ｂ細胞を枯渇させるためのｃａｒｔ１９の使用
JP2022150897A Pending JP2022173331A (ja) 2012-07-13 2022-09-22 寛容を誘導するために正常ｂ細胞を枯渇させるためのｃａｒｔ１９の使用
JP2025113498A Pending JP2025129358A (ja) 2012-07-13 2025-07-04 寛容を誘導するために正常ｂ細胞を枯渇させるためのｃａｒｔ１９の使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018082149A Withdrawn JP2018135363A (ja) 2012-07-13 2018-04-23 寛容を誘導するために正常ｂ細胞を枯渇させるためのｃａｒｔ１９の使用
JP2020113687A Withdrawn JP2020158541A (ja) 2012-07-13 2020-07-01 寛容を誘導するために正常ｂ細胞を枯渇させるためのｃａｒｔ１９の使用
JP2022150897A Pending JP2022173331A (ja) 2012-07-13 2022-09-22 寛容を誘導するために正常ｂ細胞を枯渇させるためのｃａｒｔ１９の使用
JP2025113498A Pending JP2025129358A (ja) 2012-07-13 2025-07-04 寛容を誘導するために正常ｂ細胞を枯渇させるためのｃａｒｔ１９の使用

Country Status (13)

Country Link
US (3) US20150290244A1 (enExample)
EP (1) EP2872184B1 (enExample)
JP (5) JP2015523386A (enExample)
KR (1) KR102216083B1 (enExample)
CN (2) CN120393001A (enExample)
AU (3) AU2013289984B2 (enExample)
BR (1) BR112015000657B1 (enExample)
CA (1) CA2876734A1 (enExample)
EA (2) EA201992742A3 (enExample)
ES (1) ES2835232T3 (enExample)
IN (1) IN2015DN00139A (enExample)
MX (2) MX382772B (enExample)
WO (1) WO2014012001A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018534264A (ja) * 2015-09-28 2018-11-22 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 自己免疫および同種免疫への治療的介入としてのキメラ抗原受容体（ｃａｒ）ｔ細胞
JP2019527553A (ja) * 2016-07-29 2019-10-03 ジュノー セラピューティクス インコーポレイテッド 抗ｃｄ１９抗体に対する抗イディオタイプ抗体
JP2022173331A (ja) * 2012-07-13 2022-11-18 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 寛容を誘導するために正常ｂ細胞を枯渇させるためのｃａｒｔ１９の使用

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
MX374929B (es) 2013-02-20 2025-03-06 Novartis Ag RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US10640569B2 (en) 2013-12-19 2020-05-05 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
HUE054588T2 (hu) * 2014-04-07 2021-09-28 Novartis Ag Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
ES2759260T3 (es) 2014-04-23 2020-05-08 Juno Therapeutics Inc Métodos para aislar, cultivar y modificar genéticametne poblaciones de células inmunes para la terapia adoptiva
KR102612313B1 (ko) 2014-07-21 2023-12-12 노파르티스 아게 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
CN107109420A (zh) 2014-07-21 2017-08-29 诺华股份有限公司 使用cll－1嵌合抗原受体的癌症治疗
PL3183268T3 (pl) 2014-08-19 2020-09-07 Novartis Ag Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
WO2016028879A1 (en) * 2014-08-19 2016-02-25 The Children's Hospital Of Philadelphia Compositions and methods for modulating immune response
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
WO2016044605A1 (en) 2014-09-17 2016-03-24 Beatty, Gregory Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2016057705A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
CA2972597A1 (en) * 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2016115482A1 (en) 2015-01-16 2016-07-21 Novartis Pharma Ag Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN119925616A (zh) 2015-04-08 2025-05-06 诺华股份有限公司 Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法
ES2948133T3 (es) 2015-04-17 2023-08-31 Novartis Ag Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3291679B1 (en) 2015-05-06 2021-12-15 SNIPR Technologies Limited Altering microbial populations & modifying microbiota
TWI859112B (zh) 2015-07-21 2024-10-21 瑞士商諾華公司 改良免疫細胞之功效及擴展之方法
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
JP6905163B2 (ja) 2015-09-03 2021-07-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア サイトカイン放出症候群を予測するバイオマーカー
MY196631A (en) * 2015-10-13 2023-04-24 Eureka Therapeutics Inc Antibody Agents Specific for Human Cd19 and uses Thereof
CA3006432A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
CN109069597A (zh) 2015-12-22 2018-12-21 诺华股份有限公司 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
PL3443096T3 (pl) * 2016-04-15 2023-06-19 Novartis Ag Kompozycje i sposoby do selektywnej ekspresji chimerycznych receptorów antygenowych
KR20190003550A (ko) * 2016-04-15 2019-01-09 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 키메라 동종항원 수용체 t 세포의 조성물 및 방법
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
EP3523331A1 (en) 2016-10-07 2019-08-14 Novartis AG Chimeric antigen receptors for the treatment of cancer
JP2019536786A (ja) * 2016-11-30 2019-12-19 イントレキソン コーポレーション ステロイドの投与および免疫療法
EP3346001A1 (en) * 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
SG11201907434RA (en) 2017-03-22 2019-10-30 Novartis Ag Compositions and methods for immunooncology
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
AU2019311077B2 (en) * 2018-07-23 2025-05-29 Heidelberg Pharma Research Gmbh Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
EP3833742A2 (en) 2018-08-09 2021-06-16 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
CA3111518A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods for enhancing donor oligonucleotide-based gene editing
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
AU2020336992A1 (en) 2019-08-30 2022-04-14 Yale University Compositions and methods for delivery of nucleic acids to cells
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
AU2020394441B2 (en) 2019-11-26 2025-11-13 Novartis Ag CD19 and CD22 chimeric antigen receptors and uses thereof
AU2020411823B2 (en) * 2019-12-27 2024-09-19 Zhaotai Immugene Biomedicine (Hong Kong) Limited Engineered immune killer cell, preparation method therefor and use thereof
US20230061319A1 (en) * 2020-01-10 2023-03-02 Coimmune, Inc. Methods of treating tumors
US20230265214A1 (en) 2020-08-31 2023-08-24 Yale University Compositions and methods for delivery of nucleic acids to cells
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies
CN120641131A (zh) 2022-12-01 2025-09-12 耶鲁大学 用于细胞内有效载荷递送的刺激反应性无痕工程化平台
EP4574838A1 (en) 2023-12-21 2025-06-25 Vilnius University Chimeric antigen receptor (car) with enhanced recruitment of signaling partners

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520587A (ja) * 2004-11-17 2008-06-19 アンジオゲン ファーマシューティカルズ ピーティーワイ リミテッド Ｂ細胞の機能調節のための方法
JP2008523793A (ja) * 2004-12-15 2008-07-10 ラボラトワール、フランセ、デュ、フラクショヌマン、エ、デ、ビオテクノロジ Ｂ型リンパ球様造血増殖に対する細胞傷害性抗体
WO2010102276A2 (en) * 2009-03-06 2010-09-10 Medimmune, Llc Humanized anti-cd19 antibody formulations
WO2012079000A1 (en) * 2010-12-09 2012-06-14 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012082841A2 (en) * 2010-12-14 2012-06-21 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1795588A1 (en) * 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
US9181527B2 (en) * 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
WO2011097477A1 (en) * 2010-02-04 2011-08-11 The Trustees Of The University Of Pennsylvania Icos critically regulates the expansion and function of inflammatory human th17 cells
EA201992742A3 (ru) * 2012-07-13 2020-12-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Применение cart19 для истощения нормальных b-клеток для индукции толерантности

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520587A (ja) * 2004-11-17 2008-06-19 アンジオゲン ファーマシューティカルズ ピーティーワイ リミテッド Ｂ細胞の機能調節のための方法
JP2008523793A (ja) * 2004-12-15 2008-07-10 ラボラトワール、フランセ、デュ、フラクショヌマン、エ、デ、ビオテクノロジ Ｂ型リンパ球様造血増殖に対する細胞傷害性抗体
WO2010102276A2 (en) * 2009-03-06 2010-09-10 Medimmune, Llc Humanized anti-cd19 antibody formulations
WO2012079000A1 (en) * 2010-12-09 2012-06-14 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012082841A2 (en) * 2010-12-14 2012-06-21 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 119, no. 12, JPN6017010524, March 2012 (2012-03-01), pages 2709 - 2720, ISSN: 0003526264 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 365, no. 8, JPN6017010523, 2011, pages 725 - 733, ISSN: 0003526265 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022173331A (ja) * 2012-07-13 2022-11-18 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 寛容を誘導するために正常ｂ細胞を枯渇させるためのｃａｒｔ１９の使用
JP2018534264A (ja) * 2015-09-28 2018-11-22 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 自己免疫および同種免疫への治療的介入としてのキメラ抗原受容体（ｃａｒ）ｔ細胞
JP2022023194A (ja) * 2015-09-28 2022-02-07 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 自己免疫および同種免疫への治療的介入としてのキメラ抗原受容体（ｃａｒ）ｔ細胞
JP2019527553A (ja) * 2016-07-29 2019-10-03 ジュノー セラピューティクス インコーポレイテッド 抗ｃｄ１９抗体に対する抗イディオタイプ抗体
JP7062640B2 (ja) 2016-07-29 2022-05-06 ジュノー セラピューティクス インコーポレイテッド 抗ｃｄ１９抗体に対する抗イディオタイプ抗体

Also Published As

Publication number Publication date
AU2018203756B2 (en) 2019-10-24
EA201992742A2 (ru) 2020-09-30
MX2018009820A (es) 2022-08-24
BR112015000657A8 (pt) 2018-01-16
BR112015000657B1 (pt) 2023-12-05
WO2014012001A2 (en) 2014-01-16
JP2018135363A (ja) 2018-08-30
EA201590209A1 (ru) 2015-08-31
IN2015DN00139A (enExample) 2015-06-12
AU2020200315A1 (en) 2020-02-06
ES2835232T3 (es) 2021-06-22
JP2020158541A (ja) 2020-10-01
EA034644B1 (ru) 2020-03-02
WO2014012001A3 (en) 2015-04-23
JP2022173331A (ja) 2022-11-18
CN104884095A (zh) 2015-09-02
JP2025129358A (ja) 2025-09-04
EP2872184A4 (en) 2016-03-30
EA201992742A3 (ru) 2020-12-30
AU2018203756A1 (en) 2018-06-21
AU2020200315B2 (en) 2021-11-04
BR112015000657A2 (pt) 2017-06-27
EP2872184A2 (en) 2015-05-20
AU2013289984B2 (en) 2018-03-08
EP2872184B1 (en) 2020-09-16
MX382772B (es) 2025-03-11
KR20150030750A (ko) 2015-03-20
MX2015000433A (es) 2016-04-28
KR102216083B1 (ko) 2021-02-17
US20150290244A1 (en) 2015-10-15
CN120393001A (zh) 2025-08-01
US20180271907A1 (en) 2018-09-27
AU2013289984A1 (en) 2015-01-22
US20240261328A1 (en) 2024-08-08
CA2876734A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
US20240261328A1 (en) Use of cart19 to deplete normal b cells to induce tolerance
US20230013642A1 (en) Toxicity Management for Anti-Tumor Activity of CARs
JP6293194B2 (ja) 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用
HK40116181B (en) Toxicity management for anti-tumor activity of cars
HK40116181A (en) Toxicity management for anti-tumor activity of cars
HK40069741A (en) Toxicity management for anti-tumor activity of cars
HK1253365B (en) Toxicity management for anti-tumor activity of cars
EA046588B1 (ru) Применение cart19 для лечения или предотвращения реакции "трансплантат против хозяина" (gvhd)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150409

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170928

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180612

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180618

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190426

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190710